Blandt HBeAg- positive patienter var der i uge 104 tiltagende forskel i terapeutisk respons (63% vs 48%; p < 0, 0001) og vigtigste sekundære endepunkter (middel log10 HBV DNA reduktion; - 5, 74 vs - 4, 42: p < 0, 0001, PCR negativitet:
Among HBeAg-positive patients, therapeutic response (63% vs 48%; p < 0.0001) and key secondary endpoints (mean log10 HBV DNA reduction: -5.74 vs -4.42; p < 0.0001, PCR negativity: